Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Preferred Stock Liabilities (2022 - 2023)

Sagimet Biosciences' Preferred Stock Liabilities history spans 2 years, with the latest figure at $214.6 million for Q2 2023.

  • Quarterly Preferred Stock Liabilities changed 0.0% to $214.6 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $214.6 million through Jun 2023, changed 0.0% year-over-year, with the annual reading at $214.6 million for FY2022, N/A changed from the prior year.
  • Preferred Stock Liabilities came in at $214.6 million for Q2 2023, roughly flat from $214.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $214.6 million in Q2 2022 to a low of $214.6 million in Q2 2022.